Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GR2301 in Healthy Adults
NCT07190716Phase 1Not yet recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Oct 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GR2301 in Vitiligo (5 arms), sponsored by Zhixiang Jintai. Primary endpoint: Adverse events (AEs). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
GR2301
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07190716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190716.